Nitrite or sildenafil, but not BAY 41-2272, blunt acute pulmonary embolism-induced increases in circulating matrix metalloproteinase-9 and oxidative stress

Thromb Res. 2009 Jul;124(3):349-55. doi: 10.1016/j.thromres.2008.12.006. Epub 2009 Jan 16.

Abstract

Introduction: Inhibition of matrix metalloproteinases (MMPs) improves the hemodynamics during acute pulmonary embolism (APE) and oxidative stress upregulates MMPs. We compared the effects of different NO-cGMP pathway activators on APE-induced increases in MMPs.

Materials and methods: Hemodynamic and biochemical evaluations were performed in non-embolized dogs treated with saline (N=5), and in microspheres embolized dogs receiving saline (n=9), or nitrite (6.75 micromol/kg i.v. over 15 min followed by 0.28 micromol/kg/min; n=5), or sildenafil (0.25 mg/kg; n=5), or BAY 41-2272 (0.03, 0.1, 0.3, and 1 mg/kg/h; n=5). Plasma thiobarbituric acid reactive substances (TBARS) concentrations were determined. Zymograms of plasma samples were performed, and in vitro antioxidant effects or inhibition of MMPs by these drugs were examined.

Results: APE increased mean pulmonary artery pressure by ~25 mmHg. Nitrite, BAY 41-2272, or sildenafil reversed this increase by ~40% (P<0.05). Similar effects were seen on the pulmonary vascular resistance. While both nitrite and sildenafil produced no systemic effects, the highest dose of BAY 41-2272 produced systemic hypotension (P<0.05). While nitrite and sildenafil blunted the increases in plasma pro-MMP-9 levels and TBARS (all P<0.05), BAY 41-2272 produced no such effects. Nitrite and sildenafil produced in vitro antioxidant effects and inhibited MMPs only at high concentrations. BAY 41-2272 produced no such effects.

Conclusions: Activation of the NO-cGMP pathway with nitrite or sildenafil, but not with BAY 41-2272, attenuates APE-induced oxidative stress and increased MMP-9 levels. These findings are consistent with the idea that NO-cGMP pathway activators with antioxidant effects prevent the release of MMP-9 during APE.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Disease Models, Animal
  • Dogs
  • Female
  • Humans
  • Male
  • Matrix Metalloproteinase 9 / blood*
  • Matrix Metalloproteinase Inhibitors*
  • Nitrites / administration & dosage*
  • Oxidative Stress / drug effects
  • Phosphodiesterase Inhibitors / administration & dosage
  • Piperazines / administration & dosage*
  • Pulmonary Embolism / drug therapy*
  • Pulmonary Embolism / enzymology*
  • Purines / administration & dosage
  • Pyrazoles / administration & dosage*
  • Pyridines / administration & dosage*
  • Sildenafil Citrate
  • Sulfones / administration & dosage*

Substances

  • 3-(4-Amino-5-cyclopropylpyrimidine-2-yl)-1-(2-fluorobenzyl)-1H-pyrazolo(3,4-b)pyridine
  • Matrix Metalloproteinase Inhibitors
  • Nitrites
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Pyrazoles
  • Pyridines
  • Sulfones
  • Sildenafil Citrate
  • Matrix Metalloproteinase 9